



CREATOR(S):

TITLE:

YEAR:

Original citation:

OpenAIR citation:

Copyright statement:

This work was distributed in the first instance by _____ and was originally presented at _____.

OpenAIR takedown statement:

Section 6 of the "Repository policy for OpenAIR @ RGU" (available from <http://www.rgu.ac.uk/staff-and-current-students/library/library-policies/repository-policies>) provides guidance on the criteria under which RGU will consider withdrawing material from OpenAIR. If you believe that this item is subject to any of these criteria, or for any other reason should not be held on OpenAIR, then please contact openair-help@rgu.ac.uk with the details of the item and the nature of your complaint.

This _____ is distributed under a CC _____ license.



Urban VS Rural STEMI patients; is there a difference?

A Kamona¹, S Cunningham¹, GF Rushworth², SJ Leslie³

¹ School of Pharmacy & Life Sciences Robert Gordon University, Aberdeen

² Highland Pharmacy Education & Research Centre, NHS Highland, Inverness

³ Cardiac Unit, NHS Highland, Raigmore Hospital, Inverness

✉ Ahmad.kamona@nhs.net

Introduction

Delays in ST elevation MI reperfusion result in higher death rates.¹

This study aimed to

- describe reperfusion therapy in NHS Highland.
- compare rural vs. urban patients.

Methods

All patients with STEMI between March 2014 and April 2015 were included. Patients were described as rural if >90min from Raigmore. Patient care followed one of 13 clinical pathways. (Table 1). Optimal reperfusion Therapy (ORT) was defined as the treatment which would achieve quickest reperfusion.

Driving times	Patient% (n)
≤ 30 min	37.0 (49)
30-60 min	19.0 (25)
60-90 min	6.00 (8)
90-120 min	8.00 (10)
≥ 120 min	30.0 (39)

Table 1: patients' driving time to Raigmore (N=131)




Figure 1: patients' flow diagram
STEMI: ST-elevation myocardial infarction.
NSTEMI: non ST-elevation myocardial infarction

Results

One hundred and thirty one patients were identified. In terms of initial therapy: 20% received primary percutaneous coronary intervention (PPCI), 15% received pre-hospital thrombolysis (PHT), 40% received in-hospital thrombolysis while 26% didn't receive any treatment. Overall 90% of patients received an invasive angiogram.

Pathway	Thrombolysis	Outcome of thrombolysis	PCI	Patients n(%)
1	None	N/A	PPCI	26 (20)
2	PHT	Reperfused	Convalescent	8 (6)
3	PHT	Reperfused	None	3 (2)
4	PHT	Not Reperfused	Rescue	6 (5)
5	PHT	Not Reperfused	Convalescent	2 (2)
6	PHT	Not Reperfused	None	0 (0)
7	Hospital	Reperfused	Convalescent	35 (27)
8	Hospital	Reperfused	None	3 (2)
9	Hospital	Not Reperfused	Rescue	12 (9)
10	Hospital	Not Reperfused	Convalescent	1 (1)
11	Hospital	Not Reperfused	None	1 (1)
12	None	N/A	Convalescent	26 (20)
13	None	N/A	None	8 (6)

Table 2: Reperfusion Therapy Pathway.
PPCI: primary percutaneous coronary intervention.
PHT: pre-hospital thrombolysis

Convalescent: non-urgent PCI
Rescue: PCI after failed thrombolysis

urban vs rural (cath lab open)




Figure 2 (a): urban vs. rural in Cath lab hours

urban vs rural (cath lab closed)




Figure 2 (b): urban vs. rural off Cath lab hours

Conclusion

The majority of urban patients received PPCI during working hours.

Rural patients were less likely to receive prehospital thrombolysis.

A high number of patients continue to receive thrombolysis in hospital.

There would appear to remain opportunities to improve STEMI care.

Potential barriers to optimal reperfusion therapy include:

- Patient factors (e.g. rural patients were more reluctant to call for help and present late despite on-going pain).
- Inter-hospital communication (poor communication may explain ongoing use of in hours hospital thrombolysis).
- Staffing issues (e.g. Lack of paramedic crews in remote area may explain relative under use of prehospital thrombolysis).

Funding and conflict of interest

No funding was obtained for this project.

The Authors have no conflict of interest.

References:

1. Rawls J M. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian region early anistreplase trial (GREAT). Am J Coll Cardiol 1997; 30: 1181- 6.